Company news

Share this article:

IMS Health announced the launch of its IMS Precision Compensation offering to help pharmaceutical companies optimize their sales force incentive compensation programs and gain additional cost efficiencies. To deliver this new solution, IMS has established an alliance with Callidus Software, a leading provider of sales performance management software. “Pharmaceutical companies are looking for new ways to drive commercial excellence and realize cost efficiencies, especially in non-core areas of their businesses,” said Sati Sian, general manager, Sales Force Effectiveness, IMS.

Teva Specialty Pharmaceuticals, the US respiratory therapy unit of Teva Pharmaceutical Industries and UCB announced an agreement to co-commercialize Teva's US respiratory medicines. The initial product to be jointly promoted in the US is Teva's ProAir HFA (albuterol sulfate) inhalation aerosol. ProAir HFA is the number-one branded hydrofluroalkane (HFA) albuterol sulfate inhaler in the US. Additionally, the agreement will provide UCB future joint promotion opportunities with other products in development by Teva Specialty Pharmaceuticals. Financial terms of the agreement were not disclosed.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions